STAAR Surgical Company - Asset Resilience Ratio
STAAR Surgical Company (STAA) has an Asset Resilience Ratio of 3.62% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read STAAR Surgical Company (STAA) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2001–2024)
This chart shows how STAAR Surgical Company's Asset Resilience Ratio has changed over time. See STAAR Surgical Company shareholders equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down STAAR Surgical Company's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see STAAR Surgical Company market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $16.50 Million | 3.62% |
| Total Liquid Assets | $16.50 Million | 3.62% |
Asset Resilience Insights
- Limited Liquidity: STAAR Surgical Company maintains only 3.62% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
STAAR Surgical Company Industry Peers by Asset Resilience Ratio
Compare STAAR Surgical Company's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Gan & Lee Pharmaceuticals Co Ltd
SHG:603087 |
Medical Instruments & Supplies | 9.08% |
|
Vizionfocus Inc.
TW:4771 |
Medical Instruments & Supplies | 5.07% |
|
Ansell Ltd
AU:ANN |
Medical Instruments & Supplies | 4.42% |
|
Nanosonics Ltd
AU:NAN |
Medical Instruments & Supplies | 51.82% |
|
SDI Ltd
AU:SDI |
Medical Instruments & Supplies | 6.36% |
|
Austco Healthcare Ltd
AU:AHC |
Medical Instruments & Supplies | 15.90% |
|
Trajan Group Holdings Ltd
AU:TRJ |
Medical Instruments & Supplies | 0.23% |
|
Osteopore Ltd
AU:OSX |
Medical Instruments & Supplies | 43.09% |
Annual Asset Resilience Ratio for STAAR Surgical Company (2001–2024)
The table below shows the annual Asset Resilience Ratio data for STAAR Surgical Company.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 16.94% | $86.33 Million | $509.52 Million | +9.23pp |
| 2023-12-31 | 7.71% | $37.69 Million | $488.69 Million | -22.17pp |
| 2022-12-31 | 29.88% | $125.16 Million | $418.82 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $345.78 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $67.93 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $65.44 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $62.95 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $58.91 Million | -- |
| 2013-12-31 | 0.00% | $0.00 | $61.93 Million | -- |
| 2012-12-31 | 0.00% | $0.00 | $54.76 Million | -- |
| 2011-12-31 | 0.26% | $129.00K | $49.01 Million | -0.06pp |
| 2010-12-31 | 0.33% | $133.00K | $40.59 Million | -12.28pp |
| 2009-12-31 | 12.60% | $7.40 Million | $58.68 Million | +12.26pp |
| 2008-12-31 | 0.34% | $179.00K | $52.58 Million | +0.06pp |
| 2007-12-31 | 0.28% | $150.00K | $54.18 Million | -0.04pp |
| 2006-12-31 | 0.31% | $150.00K | $47.77 Million | -9.55pp |
| 2004-12-31 | 9.86% | $5.12 Million | $51.97 Million | +6.82pp |
| 2001-12-31 | 3.04% | $2.00 Million | $65.81 Million | -- |
About STAAR Surgical Company
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) and laser-based procedures, such as LASIK to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It serve… Read more